World Library  


Add to Book Shelf
Flag as Inappropriate
Email this Book

Plos Neglected Tropical Diseases : Safety, Pharmacokinetic, and Efficacy Studies of Oral Db868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis, Volume 7

By Buscher, Philippe

Click here to view

Book Id: WPLBN0003932497
Format Type: PDF eBook :
File Size:
Reproduction Date: 2015

Title: Plos Neglected Tropical Diseases : Safety, Pharmacokinetic, and Efficacy Studies of Oral Db868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis, Volume 7  
Author: Buscher, Philippe
Volume: Volume 7
Language: English
Subject: Journels, Science, Neglected Tropical Diseases
Collections: Periodicals: Journal and Magazine Collection (Contemporary), PLoS Neglected Tropical Diseases
Historic
Publication Date:
Publisher: Plos

Citation

APA MLA Chicago

Buscher, P. (n.d.). Plos Neglected Tropical Diseases : Safety, Pharmacokinetic, and Efficacy Studies of Oral Db868 in a First Stage Vervet Monkey Model of Human African Trypanosomiasis, Volume 7. Retrieved from http://worldebooklibrary.com/


Description
Description : There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5- (N-methoxyamidino)-2-pyridyl]furan (DB868: CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection. In the infected monkeys, DB829 attained a median Cmax (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead preclinical candidate in efforts to develop a safe, short course (5–7 days), oral regimen for first stage HAT.

 

Click To View

Additional Books


  • Plos Neglected Tropical Diseases : Corre... (by )
  • Plos Neglected Tropical Diseases : the G... (by )
  • Plos Neglected Tropical Diseases : Bacte... (by )
  • Plos Neglected Tropical Diseases : Expre... (by )
  • Plos Neglected Tropical Diseases : Pheno... (by )
  • Plos Neglected Tropical Diseases : Sympt... (by )
  • Plos Neglected Tropical Diseases : the N... (by )
  • Plos Neglected Tropical Diseases : Chaga... (by )
  • Plos Neglected Tropical Diseases : ‘‘it ... (by )
  • Plos Neglected Tropical Diseases : Inter... (by )
  • Plos Neglected Tropical Diseases : Ecolo... (by )
  • Plos Neglected Tropical Diseases : Dna-s... (by )
Scroll Left
Scroll Right

 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.